<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Surgery | Nano Publications</title>
	<atom:link href="https://bibliography.nanobiotix.com/tag/surgery/feed/" rel="self" type="application/rss+xml" />
	<link>https://bibliography.nanobiotix.com</link>
	<description>Navigate through all Nanobiotix publications online</description>
	<lastBuildDate>Mon, 06 Jun 2022 05:40:56 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=6.0.1</generator>

<image>
	<url>https://bibliography.nanobiotix.com/wp-content/uploads/2019/11/cropped-n-icon-512x512-32x32.png</url>
	<title>Surgery | Nano Publications</title>
	<link>https://bibliography.nanobiotix.com</link>
	<width>32</width>
	<height>32</height>
</image> 
	<item>
		<title>2021 – Eur J Surg Oncol – STS Retrospective Study</title>
		<link>https://bibliography.nanobiotix.com/2021-eur-j-surg-oncol-sts-retrospective-study/</link>
					<comments>https://bibliography.nanobiotix.com/2021-eur-j-surg-oncol-sts-retrospective-study/#respond</comments>
		
		<dc:creator><![CDATA[nano-pub]]></dc:creator>
		<pubDate>Fri, 12 Mar 2021 11:49:27 +0000</pubDate>
				<category><![CDATA[Clinical Data NBTXR3]]></category>
		<category><![CDATA[NO-RIGHTS]]></category>
		<category><![CDATA[Publications]]></category>
		<category><![CDATA[STS]]></category>
		<category><![CDATA[Complete Response]]></category>
		<category><![CDATA[Outcomes]]></category>
		<category><![CDATA[Pathological Responsive]]></category>
		<category><![CDATA[Preoperative]]></category>
		<category><![CDATA[Retrospective Study]]></category>
		<category><![CDATA[Sarcoma]]></category>
		<category><![CDATA[Soft Tissue Sarcoma]]></category>
		<category><![CDATA[Surgery]]></category>
		<category><![CDATA[Survival]]></category>
		<guid isPermaLink="false">https://bibliography.nanobiotix.com/?p=2332</guid>

					<description><![CDATA[<p>Locally advanced soft tissue sarcoma (STS) management may include neoadjuvant or adjuvant treatment by radiotherapy (RT), chemotherapy (CT) or chemoradiotherapy (CRT) followed by wide surgical excision. While pathological complete response (pCR) to preoperative treatment is prognostic for survival in osteosarcomas, its significance for STS is unclear. We aimed to evaluate the prognostic significance of pCR to pre-operative treatment on 3-year disease-free survival (3y-DFS) in STS patients. […]</p>
The post <a href="https://bibliography.nanobiotix.com/2021-eur-j-surg-oncol-sts-retrospective-study/">2021 – Eur J Surg Oncol – STS Retrospective Study</a> first appeared on <a href="https://bibliography.nanobiotix.com">Nano Publications</a>.]]></description>
										<content:encoded><![CDATA[<div class="az-main-section-content az-module az-padding-top-0 az-padding-bottom-0 az-section-default az-section-with-equal no-animate-content az-module-bg-color">
        <div class="az-module-wrap-bg">
            <div class="az-module-wrapper-bg" style="background: #28282e;"></div>
            
        </div><div class="container-fluid az-container-no-padding"><div class="row row-parent az-gutter-0 az-equal"><div class="single-clms col-md-12 az-main-col-content az-module az-v-space-clm no-animate-content az-module-default"><div class="az-col az-clm-padding-0" ><div class="az-col-cont"><div class="row row-inner az-padding-top-0 az-padding-bottom-0 az-gutter-0 az-equal no-animate-content"><div data-animation-type="ani-in" data-animation-in="fadeInUp" data-animation-out="none" data-animation-speed="default" data-animation-delay="200" data-offset-down="90" data-offset-up="none" class="single-clms col-md-6 az-main-col-content az-module az-col-pos-middle az-v-space-clm animate-content az-module-bg-image"><div class="az-col az-clm-padding-105" data-col-min-height-default="700" data-col-min-height-sm="400" data-col-min-height-xs="350" style="min-height: 700px;">
        <div class="az-module-wrap-bg">
            <div class="az-module-wrapper-bg  az-imagesLoadedBg" style="background-image: url(https://bibliography.nanobiotix.com/wp-content/uploads/2017/02/Working-it.jpg); background-position: center center; background-repeat: no-repeat; background-size: cover;">
            
    <div class="az-module-mask-group">
        <span class="az-module-mask-bg is-bg main-mask"></span>
        
    </div>
            </div>
            
        </div><div class="az-col-cont"><div class="az-content-element-wrapper az-empty-divider hidden-lg hidden-md" style="height: 60px;"></div>
<div class="az-content-element-wrapper az-box-icon-wrapper az-margin-top-0 az-margin-bottom-0 no-animate-content">
    <div class="az-box-icon az-box-icon-top">
            <div class="az-icon-container" style="color: #ffffff; font-size: 50px;"><i class="fa fa-edit"></i>
            </div><div class="az-box-icon-content az-font-custom az-font-color-custom" style="color: #ffffff;"><h3 class="az-box-icon-title">Authors</h3><p>Sylvie Bonvalot<span class="notes up">1</span>, Jay Wunder<span class="notes up">2</span>, Alessandro Gronchi<span class="notes up">3</span>, Javier Martin Broto<span class="notes up">4</span>, Robert Turcotte<span class="notes up">5</span>, Marco Rastrelli<span class="notes up">6</span>, Zsuzsanna Papai<span class="notes up">7</span>, Stefano Radaelli<span class="notes up">3</span>, Lars H. Lindner<span class="notes up">8</span>, Felix Shumelinsky<span class="notes up">9</span>, Antonio Cubillo<span class="notes up">10</span>, Piotr Rutkowski<span class="notes up">11</span>, Clementine Demaire<span class="notes up">12</span>, Danielle Strens<span class="notes up">12</span>, Georgi Nalbantov<span class="notes up">12</span><br />
<span class="notes"><br />
1 – Department of Surgery, Institut Curie, Paris University, Paris, France<br />
2 – Department of Surgery, Sinai Health System, Toronto, Ontario, Canada<br />
3 – Department of Surgery, Fondazione IRCCS Istituto Nazionale Dei Tumori, Milan, Italy<br />
4 – Department of Medical Oncology, Hospital Virgen Del Rocio, And Institute of Biomedicine of Sevilla (IBIS) (HUVR, CSIC, University of Sevilla), Sevilla, Spain<br />
5 – Department of Surgery, McGill University Health Centre, Montreal, Quebec, Canada<br />
6 – Department of Surgical Oncology, Istituto Oncologico Veneto, Padova, Italy<br />
7 – Department of Oncology, Honved Hospital &#8211; Hungarian Defence Forces Military Hospital, Budapest, Hungary<br />
8 – Department of Medicine III, University Hospital, LMU Munich, Munich, Germany<br />
9 – Department of Surgery &#8211; Bone and Connective Tissue Tumour Surgery, Jules Bordet Institute, Brussels, Belgium<br />
10 – Department of Medical Oncology, Hospital Universitario Sanchinarro, Centro Integral Oncologico Clara Campal HM CIOCC, Madrid, Spain<br />
11 – Department of Soft Tissue/Bone Sarcoma and Melanoma, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland<br />
12 – Health Economics &amp; Outcome Research Team, Monitor Deloitte, Zaventem, Belgium<br />
</span></p>
</div></div>
</div>
<div class="az-content-element-wrapper az-empty-divider hidden-lg hidden-md" style="height: 60px;"></div></div></div></div><div data-animation-type="ani-in" data-animation-in="fadeInUp" data-animation-out="none" data-animation-speed="default" data-animation-delay="300" data-offset-down="90" data-offset-up="none" class="single-clms col-md-6 az-main-col-content az-module az-col-pos-middle az-v-space-clm animate-content az-module-bg-color"><div class="az-col az-clm-padding-105" >
        <div class="az-module-wrap-bg">
            <div class="az-module-wrapper-bg" style="background: #ffffff;"></div>
            
        </div><div class="az-col-cont"><div class="az-content-element-wrapper az-empty-divider hidden-lg hidden-md" style="height: 60px;"></div>
<div class="az-content-element-wrapper az-box-icon-wrapper az-margin-top-0 az-margin-bottom-0 no-animate-content">
    <div class="az-box-icon az-box-icon-top">
            <div class="az-icon-container" style="color: #28282e; font-size: 50px;"><i class="az-icon az-icon-layers2"></i>
            </div><div class="az-box-icon-content"><h3 class="az-box-icon-title">Summary</h3><p><strong>Background:</strong> Locally advanced soft tissue sarcoma (STS) management may include neoadjuvant or adjuvant treatment by radiotherapy (RT), chemotherapy (CT) or chemoradiotherapy (CRT) followed by wide surgical excision. While pathological complete response (pCR) to preoperative treatment is prognostic for survival in osteosarcomas, its significance for STS is unclear. We aimed to evaluate the prognostic significance of pCR to pre-operative treatment on 3-year disease-free survival (3y-DFS) in STS patients.</p>
<p><strong>Methods:</strong> This is an observational, retrospective, international, study of adult patients with primary non-metastatic STS of the extremities and trunk wall, any grade, diagnosed between 2008 and 2012, treated with at least neoadjuvant treatment and surgical resection and observed for a minimum of 3 years after diagnosis. The primary objective was to evaluate the effect of pCR. (≤5% viable tumor cells or ≥95% necrosis/fibrosis) on 3y-DFS. Effect on local recurrence-free survival (LRFS), distant recurrence-free survival (MFS) overall survival (OS) at 3 years was also analyzed. Statistical univariate analysis utilized chi-square independence test and odds ratio confidence interval (CI) estimate, multivariate analysis was performed using LASSO.</p>
<p><strong>Results</strong>: A total of 330 patients (median age 56 years old, range:19–95) treated by preoperative RT (67%), CT (15%) or CRT (18%) followed by surgery were included. pCR was achieved in 74/330 (22%) of patients, of which 56/74 (76%) had received RT. 3-yr DFS was observed in 76% of patients with pCR vs 61% without pCR (p &lt; 0.001). Multivariate analysis showed that pCR is statistically associated with better MFS (95% CI, 1.054–3.417; p = 0.033), LRFS (95% CI, 1.226–5.916; p = 0.014), DFS (95% CI, 1.165–4.040; p = 0.015) and OS at 3 years (95% CI, 1.072–5.210; p = 0.033).</p>
<p><strong>Conclusions:</strong> In a wide, heterogeneous STS population we showed that pCR to preoperative treatment is prognostic for survival.</p>
</div></div>
</div>
<div class="az-content-element-wrapper az-empty-divider hidden-lg hidden-md" style="height: 60px;"></div></div></div></div></div></div></div></div></div></div></div>The post <a href="https://bibliography.nanobiotix.com/2021-eur-j-surg-oncol-sts-retrospective-study/">2021 – Eur J Surg Oncol – STS Retrospective Study</a> first appeared on <a href="https://bibliography.nanobiotix.com">Nano Publications</a>.]]></content:encoded>
					
					<wfw:commentRss>https://bibliography.nanobiotix.com/2021-eur-j-surg-oncol-sts-retrospective-study/feed/</wfw:commentRss>
			<slash:comments>0</slash:comments>
		
		
			</item>
	</channel>
</rss>
